Risk of Cognitive Impairment in Patients With Parkinson's Disease With Visual Hallucinations and Subjective Cognitive Complaints
Por:
Santos-Garcia, D, Fonticoba, TD, Bartolome, CC, Painceiras, MJF, Gonzalez, JMP, Miro, CM, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira, V, Puente, V, Garcia-Soto, JD, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Kulisevsky, J, Estrada, MB, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues, O, Ardura, JG, Redondo, RA, Ordas, C, Diaz, LMLL, McAfee, D, Martinez-Martin, P, Mir, P
Publicada:
1 jul 2023
Ahead of Print:
2 ene 2023
Resumen:
Background and Purpose Visual hallucinations (VH) and subjective cognitive complaints (SCC) are associated with cognitive impairment (CI) in Parkinson's disease. Our aims were to determine the association between VH and SCC and the risk of CI development in a cohort of patients with Parkinson's disease and normal cognition (PD-NC). Methods Patients with PD-NC (total score of >80 on the Parkinson's Disease Cognitive Rating Scale [PD-CRS]) recruited from the Spanish COPPADIS cohort from January 2016 to November 2017 were followed up after 2 years. Subjects with a score of & GE;1 on domain 5 and item 13 of the Non-Motor Symptoms Scale at baseline (V0) were considered as "with SCC" and "with VH," respectively. CI at the 2-year follow-up (plus or minus 1 month) (V2) was defined as a PD-CRS total score of <81. Results At V0 (n=376, 58.2% males, age 61.14 & PLUSMN;8.73 years [mean & PLUSMN;SD]), the frequencies of VH and SCC were 13.6% and 62.2%, respectively. VH were more frequent in patients with SCC than in those without: 18.8% (44/234) vs 4.9% (7/142), p<0.0001. At V2, 15.2% (57/376) of the patients had developed CI. VH presenting at V0 was associated with a higher risk of CI at V2 (odds ratio [OR]=2.68, 95% confidence interval=1.05-6.83, p=0.039) after controlling for the effects of age, disease duration, education, medication, motor and nonmotor status, mood, and PD-CRS total score at V0. Although SCC were not associated with CI at V2, presenting both VH and SCC at V0 increased the probability of having CI at V2 (OR=3.71, 95% confidence interval=1.36-10.17, p=0.011). Conclusions VH were associated with the development of SCC and CI at the 2-year follow-up in patients with PD-NC.
Filiaciones:
Santos-Garcia, D:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Fonticoba, TD:
Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain
Bartolome, CC:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Painceiras, MJF:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Gonzalez, JMP:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Miro, CM:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Jesus, S:
Univ Seville, Hosp Univ Virgen Rocio,Inst Biomed Sevilla, CSIC,Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedad Neurode, Madrid, Spain
Pastor, P:
Hosp Univ Mutua Terrassa, Terrassa, Spain
Planellas, L:
Clin Pilar, Barcelona, Spain
Cosgaya, M:
Hosp Clin Barcelona, Barcelona, Spain
Caldentey, JG:
Ctr Neurol Oms 42, Palma de Mallorca, Spain
Caballol, N:
Hosp Moises Broggi, Consorci Sanitari Integral, Sant Joan Despi, Spain
Legarda, I:
Hosp Univ Son Espases, Palma De Mallorca, Spain
Vara, JH:
Hosp Univ Vall dHebron, Barcelona, Spain
Cabo, I:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Manzanares, LL:
Hosp Univ Princesa, Madrid, Spain
Aramburu, IG:
CIBERNED Ctr Invest Biomed Red Enfermedad Neurode, Madrid, Spain
Hosp Univ Marques Valdecilla, Santander, Spain
Rivera, MAA:
Hosp Gen LHospitalet, Consorci Sanitari Integral, Lhospitalet De Llobregat, Spain
Mayordomo, VG:
Hosp Univ Clin San Carlos, Madrid, Spain
Nogueira, V:
Hosp Costa Burela, Lugo, Spain
Puente, V:
Hosp Mar, Barcelona, Spain
Garcia-Soto, JD:
Hosp Univ Virgen Macarena, Seville, Spain
Borrue, C:
Hosp Infanta Sofia, Madrid, Spain
Vila, BS:
Inst Catala Salut, Inst Assistencia Sanitaria IAS, Girona, Spain
Sauco, MA:
Hosp Gen Univ Elche, Elche, Spain
Vela, L:
Fundac Hosp Alcorcon, Madrid, Spain
Escalante, S:
Hosp Tortosa Verge Cinta HTVC, Tortosa, Spain
Cubo, E:
Complejo Asistencial Univ Burgos, Burgos, Spain
Padilla, FC:
Hosp Univ Canarias, San Cristobal De La Lagu, Spain
Castrillo, JCM:
RYCIS, Hosp Univ Ramon y Cajal, Madrid, Spain
Alonso, PS:
Hosp Univ Puerta Hierro, Madrid, Spain
Losada, MGA:
Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain
Ariztegui, NL:
Complejo Hosp Toledo, Toledo, Spain
Gaston, I:
Complejo Hosp Navarra, Pamplona, Spain
Kulisevsky, J:
Hosp Sant Pau, Barcelona, Spain
Estrada, MB:
Hosp Univ Cent Asturias, Oviedo, Spain
Martinez, JR:
Hosp Univ Donostia, San Sebastian, Spain
Valero, C:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Hosp Arnau Vilanova, Valencia, Spain
Hosp Ruber Int, Madrid, Spain
de Fabregues, O:
Hosp Univ Vall dHebron, Barcelona, Spain
Ardura, JG:
Hosp Cabuenes, Gijon, Spain
Redondo, RA:
Univ Lucus Augusti HULA, Lugo, Spain
Ordas, C:
Hosp Rey Juan Carlos, Madrid, Spain
Diaz, LMLL:
Complejo Hosp Univ Orense CHUO, Orense, Spain
McAfee, D:
Univ Maryland, Sch Med, Baltimore, MD USA
Martinez-Martin, P:
CIBERNED Ctr Invest Biomed Red Enfermedad Neurode, Madrid, Spain
Mir, P:
Univ Seville, Hosp Univ Virgen Rocio,Inst Biomed Sevilla, CSIC,Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedad Neurode, Madrid, Spain
gold
|